“Centella asiatica water” is generally a commercial raw-material name, and the specific manufacturing process cannot be determined from the name alone. It may refer to:
① a Centella asiatica distillate;
② an aqueous Centella asiatica extract;
③ a low-concentration solution of Centella ...
RAS mutations drive many tumors, including pancreatic cancer, colorectal cancer, and lung cancer. However, RAS was long considered difficult to drug because of its shallow structural pockets and tight GTP binding. The emergence of RAS(ON) inhibitors, molecular glues, and PROTACs has shifted RAS ...
Nanobodies have the characteristics of small molecular size, high epitope accessibility, and flexible engineering potential, and can be used in tumor molecular imaging, targeted delivery, immune regulation, and engineered cell therapy.
ENTPD3 regulates islet purinergic signaling by hydrolyzing extracellular ATP and ADP, and can be used for live identification, sorting, and secretion function studies of adult islet β cells.
Peptide drugs consist of specific amino acid sequences and can exert their effects through receptor agonism or antagonism, regulation of enzymes and ion channels, interference with protein-protein interactions, and targeted delivery. Their molecular size lies between that of conventional ...
Protein post-translational modifications (PTMs) broadly refer to covalent processing events that occur during or after translation, including proteolytic cleavage and the covalent addition or removal of chemical groups, small molecules, or protein modifiers, thereby regulating protein activity, ...
Targeted covalent inhibitors (TCIs) first form a noncovalent complex with the target protein and then form a covalent bond with a specific amino acid residue near the binding pocket. Their development focuses on increasing target occupancy and duration of action while controlling warhead ...
GM-CSF, IL-3, and IL-5 integrate hematopoietic and immune signals through the shared βc chain, respectively regulating myeloid cells, basophils, and eosinophils, and participating in hematologic malignancies, allergy, and autoimmune inflammation.
Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ...
Wir verwenden Cookies, um die ordnungsgemäße Funktion der Website sicherzustellen und, soweit zulässig, Ihr Nutzererlebnis zu verbessern. Sie können Ihre Einstellungen jederzeit unter „Einstellungen“ verwalten. Weitere Informationen finden Sie in unserer Cookie-Richtlinie.
Dürfen wir Sie über Rabattaktionen informieren?
Später erinnern
Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.